CN111748003B - N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针 - Google Patents
N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针 Download PDFInfo
- Publication number
- CN111748003B CN111748003B CN202010588544.XA CN202010588544A CN111748003B CN 111748003 B CN111748003 B CN 111748003B CN 202010588544 A CN202010588544 A CN 202010588544A CN 111748003 B CN111748003 B CN 111748003B
- Authority
- CN
- China
- Prior art keywords
- acetamido
- nitrophthalimide
- probe
- galactose
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000523 sample Substances 0.000 title claims abstract description 47
- 229930182830 galactose Natural products 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 210000004185 liver Anatomy 0.000 title abstract description 16
- 230000008685 targeting Effects 0.000 title abstract description 10
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 41
- 238000001514 detection method Methods 0.000 claims abstract description 21
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 9
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 76
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- -1 amino Chemical group 0.000 claims description 9
- VEVGTTUIMHJYSO-UHFFFAOYSA-N 2-(4-nitro-1,3-dioxoisoindol-2-yl)acetic acid Chemical class C1=CC([N+]([O-])=O)=C2C(=O)N(CC(=O)O)C(=O)C2=C1 VEVGTTUIMHJYSO-UHFFFAOYSA-N 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000006722 reduction reaction Methods 0.000 claims description 6
- QKPLRMLTKYXDST-WNFIKIDCSA-N (2s,3r,4r,5r,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O QKPLRMLTKYXDST-WNFIKIDCSA-N 0.000 claims description 4
- ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- CGJFKQFYZOARRV-UHFFFAOYSA-N 2-(2-azidoethoxy)ethanol Chemical compound OCCOCCN=[N+]=[N-] CGJFKQFYZOARRV-UHFFFAOYSA-N 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- FRKYZIHMQZATAH-JRTVQGFMSA-N (2r,3s,4s,5r)-n-acetyl-2,3,4,5,6-pentahydroxyhexanamide Chemical compound CC(=O)NC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FRKYZIHMQZATAH-JRTVQGFMSA-N 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 abstract description 8
- 230000004044 response Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- BONIIQYTWOPUQI-UHFFFAOYSA-N 4-nitroisoindole-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)NC2=O BONIIQYTWOPUQI-UHFFFAOYSA-N 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 238000000799 fluorescence microscopy Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 238000002189 fluorescence spectrum Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 241000252212 Danio rerio Species 0.000 description 7
- JYHHJVKGDCZCCL-UHFFFAOYSA-J carbon monoxide;dichlororuthenium Chemical compound [O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].Cl[Ru]Cl.Cl[Ru]Cl JYHHJVKGDCZCCL-UHFFFAOYSA-J 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 102000016761 Haem oxygenases Human genes 0.000 description 2
- 108050006318 Haem oxygenases Proteins 0.000 description 2
- YWODDYWCAPEALG-MAEOEUOPSA-N N-[2-[2-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethoxy]ethyl]-2-(4-nitro-1,3-dioxoisoindol-2-yl)acetamide Chemical compound CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OCCOCCNC(=O)CN2C(=O)C3=C(C2=O)C(=CC=C3)[N+](=O)[O-])CO)O)O YWODDYWCAPEALG-MAEOEUOPSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000003278 haem Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000003421 catalytic decomposition reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 101150086731 ges-1 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000010496 root system development Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000014793 stomatal movement Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明提供了一种N‑乙酰胺基半乳糖修饰的3‑硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针。本发明荧光探针的制备方法简单，所得荧光探针以N‑乙酰胺基半乳糖为肝靶向基团，3‑硝基邻苯二甲酰亚胺为CO响应基团，可作为CO的检测试剂，选择性好、灵敏度高，能够靶向于肝细胞和肝组织，能够用于动态监测CO水平。
Description
技术领域
本发明涉及一种荧光探针，具体地说是涉及一种N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、其制备方法与应用及肝靶向荧光探针。
背景技术
一氧化碳（CO）是一种无色无味的气体分子，可以和氧气竞争性结合血红蛋白，人类过量吸入会造成窒息死亡，被称为危害人类的“隐形杀手”，一直以来，被认为是一种气态环境污染物。近年来研究发现，CO是植物和动物体内一种内源性气体信号分子，其在维系动植物正常运行过程中扮演者重要的角色。动植物内源性CO均主要由血红素氧合酶（HO）催化分解亚铁血红素（heme）产生。植物内源性CO可以植物生长发育调节，如对逆境（如高盐、重金属、紫外线、活性氧等）响应、气孔运动、根系发育，以及与其他信号分子的相互作用等。动物内源性CO可以激活鸟苷酸环化酶活性、参与呼吸节律调节、缓解氧化应激、调节胰岛素释放和降低血压等。此外，相关研究发现内源性CO浓度异常与多种疾病的发生发展密切相关，包括神经退行性病变、心血管疾病、肺病、糖尿病、肥胖症、败血症和癌症等。因此，开发“可视化”内源CO的检测方法，是CO生物学功能和疾病诊断等相关研究发展迫切需要解决的问题之一。
CO的传统检测方法主要有电化学法、气相色谱法和比色法，这些都不适合活细胞和活体中实时、动态观测CO。相比之下，荧光探针法因其选择性好、灵敏度高、操作简便、实时检测，对生物样品无破坏性损伤以及适用于细胞和活体荧光成像等特点，已被广泛应用于活细胞和活体内多种生物分子的检测。CO的化学性质相对稳定，在生理条件下，能直接参与的化学反应较少。因此，与检测其他内源性活性分子的荧光探针相比，CO荧光探针的研究尚未成熟，仍有较大的发展空间。当前报道的CO荧光探针主要有三类：环钯金属配合物二聚体荧光探针、烯丙基醚/碳酸酯/碳酸酰胺二组分荧光探针和芳香硝基还原型荧光探针。其中，芳香硝基还原型荧光探针因其制备简单、使用方便受到广泛关注，但其仍存在选择性不高、灵敏度低以及对肝细胞和肝组织无靶向递送能力等问题。因此，发展选择性好、灵敏度高，靶向于肝细胞和肝组织以及能够动态监测CO水平的芳香硝基还原型荧光探针具有重要意义。
发明内容
本发明的目的之一是提供一种N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物。
本发明的目的之二是提供前述N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物的制备方法。
本发明的目的之三是提供前述N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物作为探针在检测一氧化碳，或荧光光谱检测，或细胞、活体成像中的应用。
本发明的目的之四是提供一种肝靶向荧光探针。
本发明的目的之五是提供一种一氧化碳的检测方法。
本发明的目的之一是这样实现的：
一种N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物，其化学分子式为C22H28N4O12，化学结构式如式I所示：
式I。
所述N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物的化学名称为：N-(2-(2-(((2R,3R,4R,5R,6R)-3-乙酰胺基-4,5-二羟基-6-(羟甲基)四氢化-2H-吡喃-2-烷基)氧杂)乙氧基)乙基)-2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酰胺；
英文名称为：
N-(2-(2-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethyl)-2-(4-nitro-1,3-dioxoisoindolin-2-yl)acetamide。
本发明的目的之二是这样实现的：
前述N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物的制备方法，包括如下步骤：
（a）以3-硝基邻苯二甲酸酐为原料，在冰醋酸回流的条件下，与甘氨酸反应，得到2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸；
（b）以D-(+)-半乳糖胺盐酸盐为原料，依次与乙酸酐发生乙酰化反应、与三氟甲磺酸三甲基硅酯和1,5-二氨基-3-氧杂戊烷发生糖苷化反应、与钯碳和氢气发生还原反应，得到端位氨基修饰的N-乙酰胺基半乳糖；
（c）2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸与端位氨基修饰的N-乙酰胺基半乳糖发生酰胺化反应，在三乙胺碱性条件下脱除乙酸酯基，得到N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物。
步骤（a）中，具体地，将3-硝基邻苯二甲酸酐、甘氨酸加入反应容器中，向其中加入冰醋酸，回流反应过夜，减压蒸除溶剂，甲醇重结晶，抽滤，干燥即得2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸。
步骤（b）中，发生乙酰化反应时，将D-(+)-半乳糖胺盐酸盐溶解于无水吡啶中，分别加无水三乙胺和DMAP，冰水下滴加乙酸酐，滴完后升至室温，搅拌过夜；将白色固体过滤，经甲苯洗、水洗，干燥得白色固体化合物2。
发生糖苷化反应时，将化合物2溶解于无水1,2-二氯乙烷中，滴加三氟甲磺酸三甲基硅酯，搅拌过夜，将NaHCO3溶解于冰水中，剧烈搅拌下将反应液倾入，继续搅拌30 min，依次经过二氯甲烷萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩得化合物3；将化合物3溶解于无水1,2-二氯乙烷中，加入1-羟基-5-叠氮-3-氧杂戊烷，滴加TMSOTf，室温搅拌4 h，将反应液缓慢倾入冷的NaHCO3水溶液，继续搅拌0.5 h，依次经二氯甲烷萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩得化合物4。
发生还原反应时，将化合物4溶解于无水四氢呋喃中，加入Pd/C，通入氢气（压力为20 bar），室温反应24 h；减压蒸除溶剂，得到端位氨基修饰的N-乙酰胺基半乳糖。
步骤（c）中，具体地，2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸与端位氨基修饰的N-乙酰胺基半乳糖发生酰胺化反应，在三乙胺碱性条件下脱除乙酸酯基，得到N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物。
将2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸和HATU溶于DMF中，室温搅拌15min；加入端位氨基修饰的N-乙酰胺基半乳糖和DIPEA，室温反应4 h；经二氯甲烷萃取，饱和食盐水洗，无水Na2SO4干燥，浓缩，得到白色固体化合物；将其溶于甲醇中，加入三乙胺，50℃反应24 h；减压蒸除溶剂，柱层析纯化，得到N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物。
本发明的目的之三是这样实现的：
前述在检测一氧化碳，或荧光光谱检测，或细胞、活体成像中的应用。
优选地，前述N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物作为探针在检测肝细胞或肝组织中的一氧化碳的应用，特别是采用荧光成像原位检测肝细胞或肝组织中的一氧化碳。
本发明的目的之四是这样实现的：
一种肝靶向荧光探针，其化学分子式为C22H28N4O12，其化学结构式如式I所示：
式I。
所示肝靶向荧光探针的化学名称为：N-(2-(2-(((2R,3R,4R,5R,6R)-3-乙酰胺基-4,5-二羟基-6-(羟甲基)四氢化-2H-吡喃-2-烷基)氧杂)乙氧基)乙基)-2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酰胺，
英文名称为：
N-(2-(2-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethyl)-2-(4-nitro-1,3-dioxoisoindolin-2-yl)acetamide。
所述肝靶向荧光探针可以实现对肝细胞或肝组织中CO的动态监测。
在CO浓度为10~100 μM时，荧光探针的荧光强度值y（F509nm）与CO浓度x（μM）的线性回归方程为y=125.39+2.90x。
荧光探针与CO反应后，溶液荧光由无色变为绿色，对CO具有高选择性。
荧光探针对CO的检测极限为19.2 nM。
荧光探针在pH为4~10的范围内，均可与CO呈现荧光响应。
荧光探针对于肝HepG2细胞内CO、APAP诱导斑马鱼肝脏内源性CO等的荧光成像检测。
本发明的目的之五是这样实现的：
利用I所示的N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、肝靶向荧光探针检测CO浓度的方法，其采用荧光光谱法检测样品中CO的浓度。
可选地，采用荧光光谱法检测样品中CO的浓度，包括如下步骤：
（1）配制pH=7.4，浓度为10 mM的PBS缓冲液，备用；配制浓度为5 mM的式I所示肝靶向荧光探针的DMSO溶液，备用；配制浓度为10 mM CORM-2的DMSO溶液，备用。
（2）将2 mL PBS缓冲液、4 μL的式I所示肝靶向荧光探针的DMSO溶液和20 μL的CORM-2的DMSO溶液，依次加入到干净的荧光比色皿中，在荧光光谱仪上检测，在509 nm处有最大发射峰，随着待测样的加入，最大发射峰强度逐渐增强；
（3）将2 mL PBS缓冲液和4 μL的式I所示肝靶向荧光探针的DMSO溶液加入到荧光比色皿中，然后逐渐加入浓度为10 mM的CORM-2的DMSO溶液，当累积加入的CORM-2的DMSO溶液的体积分别为2 μL、4 μL、8 μL、12 μL、16 μL、20 μL时，荧光光谱仪上测定509 nm处对应的发射峰值分别为151.10、187.10、250.25、318.40、354.45、395.90；然后以比色皿中CO的浓度为横坐标，以509 nm处的荧光强度为纵坐标绘制图，得到CO浓度工作曲线；根据所述工作曲线拟合得到荧光强度值y（F509nm）与CO浓度x（μM）的线性回归方程为y=125.39+2.90x；
（4）将2 mL PBS缓冲液和4 μL的式I所示肝靶向荧光探针的DMSO溶液加入到荧光比色皿中，然后逐渐加入V μL的待测样品溶液，在荧光光谱仪上测定509 nm对应的发射峰值，然后将其代入步骤（3）所述的线性回归方程，将所得x值代入待测样品CO浓度计算公式C待测样=(2000+V) μL*x*10-6/V μL，可得待测样品中一氧化碳浓度C待测样的值。
本发明制备得到了一种N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物I，该化合物以3-硝基邻苯二甲酰亚胺为CO响应基团，以N-乙酰胺基半乳糖为肝靶向基团，可作为CO的检测试剂，对CO显示了极高的选择性和极低的检测限，能够靶向于肝细胞和肝组织，能够用于动态监测肝细胞和肝组织内源性CO变化。
附图说明
图1是肝靶向荧光探针与CO反应的荧光动力学测试结果，插图为荧光探针在509nm处的荧光发射峰强度与反应时间的拟合图。
图2是肝靶向荧光探针的荧光选择性测试结果。
图3是肝靶向荧光探针与CO反应溶液的荧光光谱测试结果，插图为荧光探针与CO反应溶液在509 nm处的荧光发射峰强度与10~100 μM浓度CO的线性关系结果。
图4是不同pH缓冲溶液中肝靶向荧光探针与CO反应前后509 nm处荧光强度结果。
图5是肝靶向荧光探针的细胞选择性荧光成像结果。
图6是肝靶向荧光探针用于肝细胞外源性CO的荧光成像结果。
图7是肝靶向荧光探针用于APAP诱导斑马鱼肝脏内源性CO的荧光成像结果。
具体实施方式
下面结合实施例对本发明做进一步的阐述，下述实施例仅作为说明，并不以任何方式限制本发明的保护范围。
在下述实施例中未详细描述的过程和方法是本领域公知的常规方法，实施例中所用试剂均为分析纯或化学纯，且均可市购或通过本领域普通技术人员熟知的方法制备。下述实施例均实现了本发明的目的。
实施例1
采用如下方式合成目标化合物，合成路线如下：
化合物2：
将2.15 g（10.0 mmol）化合物1盐即D-(+)-半乳糖胺盐酸盐溶解于20 mL无水吡啶中，分别加入1 mL无水三乙胺和122 mg（1.00 mmol）DMAP，冰水下滴加5.67 mL（60.0 mmol）乙酸酐，滴完后升至室温，搅拌过夜。将白色固体过滤，依次经过10 mL甲苯洗，50 mL水洗，干燥得3.35 g白色固体化合物2（产率86%）。
1 δ (ppm) 7.90 (d, J = 9.2 Hz, 1H), 5.63 (d, J = 8.8 Hz, 1H), 5.26(s, 1H), 5.06 (d, J = 9.6 Hz, 1H), 4.22 (s, 1H), 4.03-3.99 (m, 3H), 2.11 (s,3H), 2.03 (s, 3H), 1.98 (s, 3H), 1.90 (s, 3H), 1.78 (s, 3H). 13C NMR (100 MHz,DMSO): δ (ppm) 170.4, 170.3, 170.1, 170.0, 169.4, 71.2, 70.4, 66.8, 61.8,48.5, 23.1, 20.9, 20.8.
化合物3：
将1.95 g（5.00 mmol）化合物2溶解于20 mL无水1,2-二氯乙烷中，滴加1.08 mL（6.00 mmol）三氟甲磺酸三甲基硅酯（TMSOTf），滴完后，搅拌过夜。将840 mg（10.0 mmol）NaHCO3溶解于50 mL冰水中，剧烈搅拌下将反应液倾入，继续搅拌30 min。依次经过二氯甲烷萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩得化合物3淡黄色粘稠液体1.65 g，定量产率。未分离直接进行下一步。
1 3 δ (ppm) 5.90 (d, J = 6.8 Hz, 1H), 5.36 (s, 1H), 4.80 (s, 1H), 4.15-4.02 (m, 3H), 3.90 (s, 1H), 2.11 (s, 3H), 2.03 (s, 3H), 1.97 (s, 9H). 13C NMR(100 MHz, CDCl3): δ (ppm) 170.2, 170.0, 169.6, 166.1, 101.2, 71.5, 69.2,65.0, 63.3, 61.3, 20.5, 20.4, 20.3, 14.2.
化合物4：
将1.65 g（5.00 mmol）化合物3溶解于20 mL无水1,2-二氯乙烷中，加入786 mg（6.00 mmol）2-(2-叠氮乙氧基)乙醇，滴加181 μL（1.00 mmol）TMSOTf。室温搅拌4 h。将反应液缓慢倾入冷的NaHCO3水溶液，继续搅拌0.5 h。依次经过二氯甲烷萃取，饱和食盐水洗，无水硫酸钠干燥，浓缩得化合物4淡黄色粘稠液体1.84 g，两步产率80%。
1 3 δ (ppm) 5.82 (d, J = 8.8 Hz, 1H), 5.33 (d, J = 2.8 Hz, 1H), 5.18(dd, J = 3.2 Hz, J = 11.2 Hz, 1H), 4.74 (d, J = 8.4 Hz, 1H), 4.17-4.02 (m,3H), 3.96-3.88 (m, 2H), 3.79-3.74 (m, 1H), 3.64-3.60 (m, 4H), 3.45-3.35 (m,2H), 2.13 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H).
化合物5：
将460 mg化合物4（1.00 mmol）溶解于10 mL无水四氢呋喃中，加入40 mg Pd/C，通入氢气（压力为20 bar），室温反应24 h。然后减压蒸除溶剂，得到黄色固体5即端位氨基修饰的N-乙酰胺基半乳糖，无需纯化，可直接用于后续反应。
化合物7：
将1.93 g 3-硝基邻苯二甲酸酐（10 mmol）和0.826 g甘氨酸（11 mmol）加入50 mL圆底烧瓶中，加入20 mL冰醋酸，回流反应过夜。然后减压蒸除溶剂，甲醇重结晶，抽滤，干燥，得2.28 g白色固体7即2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸（91%）。
1 d 6：δ (ppm): 13.38 (s, 1H), 8.35 (d, J = 8.0 Hz, 1H), 8.25 (d, J = 7.6Hz, 1H), 8.11 (t, J = 8.0 Hz, 1H), 4.35 (s, 2H).
式I目标化合物HEP-CO:
将250 mg化合物7（1 mmol）和HATU（570 mg, 1.5 mmol）溶于8 mL DMF中，室温搅拌15 min。依次加入434 mg化合物5（1 mmol）和523 μL DIPEA（3 mmol），室温反应4 h。依次经二氯甲烷萃取，饱和食盐水洗，无水Na2SO4干燥，浓缩，得到白色固体化合物。将其溶于5mL甲醇中，加入33 μL三乙胺（1 mmol），50 ℃反应24 h。减压蒸除溶剂，柱层析（v(二氯甲烷/甲醇) = 5/1）纯化，得55.1 mg白色固体荧光探针HEP-CO即N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物（20%）。
1 d 6 δ (ppm): 8.31 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.09(t, J = 7.6 Hz, 1H), 4.27 (d, J = 8.8 Hz, 1H), 4.22 (s, 2H), 3.81 - 3.76 (m,1H), 3.73 - 3.66 (m, 1H), 3.63 (d, J = 3.2 Hz, 1H), 3.50 - 3.46 (m, 4H), 3.43- 3.38 (m, 3H), 3.31 (t, J = 6.0 Hz, 1H), 3.25 - 3.18 (m, 2H), 1.80 (s, 3H);13C NMR (101 MHz, DMSO-d 6):δ (ppm): 170.4, 170.3, 166.3, 166.3, 166.1, 163.5,144.8, 137.0, 134.0 129.0, 127.6, 123.5, 101.8, 75.7, 71.7, 69.9, 69.3, 68.0,67.9, 60.9, 52.4, 46.2, 41.0, 23.5, 23.4. HRMS (C22H29N4O12): Cald for541.1776, found 541.1768.
实施例2
将实施例1所得目标化合物进行光谱性能测试。
1、探针母液的配制
准确称量5.4048 mg探针固体，用2 mL无水DMSO溶解，配制成浓度为5 mM的探针母液；以CORM-2 (CAS: 22549-69-0)作为CO释放分子，准确称量5.1201 mg CORM-2固体，用无水DMSO溶解，配制成浓度为5 mM的CO母液；测试溶液为磷酸盐缓冲体系(10 mM, pH =7.4)。
2、探针与CO反应动力学测试
向2 mL PBS中，依次加入探针分子HEP-CO (10 μM)和CO (100 μM)，37度下检测反应时间0-40 min内探针溶液的荧光发射光谱，其中，激发波长为420 nm，发射波长收集范围为440-700 nm，激发和发射狭缝宽度均为10 nm。所得结果如图1所示。从图中可以看出，加入CO后，探针反应迅速。
3、探针对CO选择性光谱检测
选取阴阳离子（Fe3+、Mg2+、Cu2+、NO3 -、NO2 -、SO3 2-）活性硫物种（H2S、Cys、Hcy、GSH），活性氮物种（NO），活性氧物种（ONOO-、H2O2、NaClO、KO2、t-BuOOH），其它。
选择性测试条件：向2 mL PBS中，依次加入探针分子HEP-CO (10 μM)、不同干扰分子或CO (100 μM)。其中，Cys、Hcy浓度为1 mM，GSH浓度为5 mM，其余干扰分子浓度均为100μM，37度下反应60 min。所得结果如图2所示。从图中可以看出，探针对CO具有高选择性。
4、探针对CO的检测范围与检测极限测试
向2 mL PBS中，依次加入探针HEP-CO (10 μM)和不同浓度的CO (10, 20, 40,60, 80, 100 μM)，37度下反应30 min。分别检测上述探针溶液的荧光发射光谱，所得结果如图3所示，在CO浓度为10~100 μM时，荧光探针的荧光强度值y（F509nm）与CO浓度x（μM）的线性回归方程为y=125.39+2.90x。
向2 mL PBS中，依次加入探针HEP-CO (10 μM)和不同浓度的CO (0, 2, 4, 6, 8,10 μM)，37度下反应30 min，分别检测上述探针溶液的荧光发射光谱。单独测试12次仅加入探针HEP-CO (10 μM)的荧光发射光谱，计算509 nm处的荧光强度值的标准偏差（σ）；对低浓度CO（0-10 μM）与探针反应的荧光发射光谱中509 nm处的荧光强度值与CO浓度进行线性拟合，得到直线斜率k。通过公式计算检测极限LOD = 3*σ/k。探针对CO的检测极限为19.2 nM。
5、探针对CO在不同pH下的光谱检测
配制不同pH（4.0、5.0、6.0、7.0、8.0、9.0、10.0）的PBS (10 mM)。向不同pH的PBS中，依次加入探针HEP-CO (10 μM)和CO (100 μM)，37度下作用30 min。然后分别检测不同pH下的探针与CO反应前后溶液的荧光发射光谱，所得结果如图4所示。在pH 4-10范围内，探针与CO反应后，均呈现较大的荧光响应，具有较宽的pH适用范围。
实施例3
细胞选择性实验
选用人肝癌HepG2、人宫颈癌Hela、人非小细胞肺癌A549和人胃粘膜上皮细胞癌GES-1四种细胞作为研究对象。将四种细胞分别培养至贴壁，第一组实验中，分别向各种细胞中加入探针HEP-CO (10 μM, 2 mL)，与细胞共孵育1 h；第二组实验中，分别向各种细胞中加入探针HEP-CO (10 μM, 2 mL)，与细胞共孵育1 h后，用生理PBS清洗三次，以除去过量的探针，再加入CO (100 μM, 2 mL)，继续孵育30 min。利用激光共聚焦显微镜，对上述细胞进行荧光成像。选择405 nm激光器，绿色荧光通道收集475 - 575 nm范围内的信号。所得结果如图5所示，则探针可以选择性靶向肝HepG2细胞，用于HepG2细胞内CO的荧光成像检测。
实施例4
细胞外源性CO的荧光成像
选用人肝癌HepG2细胞作为研究对象。将四种细胞分别培养至贴壁，对照组，仅对细胞成像；实验组，分别向细胞中加入探针HEP-CO (10 μM, 2 mL)，与细胞共孵育1 h后，用生理PBS清洗三次，以除去过量的探针，再分别加入不同浓度CO (50 μM、200 μM)的细胞培养液(2 mL)，继续孵育30 min。利用激光共聚焦显微镜，对上述细胞进行荧光成像。选择405nm激光器，绿色荧光通道收集475 – 575 nm范围内的信号。所得结果如图6所示，则探针可用于HepG2细胞内外源性CO的荧光成像检测。
实施例5
对乙酰氨基酚(APAP)诱导斑马鱼肝脏内源性CO的荧光成像：
斑马鱼受精卵在E3培养液中，28℃下控光（光照14 h/黑暗10 h）培育至5-7日龄，进行荧光成像实验。第一组实验中，向培养液中加入探针HEP-CO (10 μM)，培育1 h；第二组实验中，向培养液中加入APAP (2 mM)，用培养液清洗斑马鱼三次以除去过量APAP，再加入探针HEP-CO (10 μM)，培育1 h，用E3培养液清洗斑马鱼三次除去过量探针。利用激光共聚焦显微镜，对上述细胞进行荧光成像。选择405 nm激光器，绿色荧光通道收集475 -575 nm范围内的信号。所得结果如图7所示，则探针可以用于APAP诱导斑马鱼肝脏内源性CO的荧光成像检测。
Claims (5)
1.一种N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物，其特征在于，化学分子式为C22H28N4O12，化学结构式如式I所示：
式I。
2.权利要求1所述的N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物的制备方法，其特征在于，包括如下步骤：
（a）以D-(+)-半乳糖胺盐酸盐为原料，依次与乙酸酐发生乙酰化反应、与三氟甲磺酸三甲基硅酯和2-(2-叠氮乙氧基)乙醇发生糖苷化反应、与钯碳和氢气发生还原反应，得到端位氨基修饰的N-乙酰胺基半乳糖；合成路线如下所示：
（b）以3-硝基邻苯二甲酸酐为原料，在冰醋酸回流的条件下，与甘氨酸反应，得到2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸；2-(4-硝基-1,3-二氧代异吲哚啉-2-基)乙酸与端位氨基修饰的N-乙酰胺基半乳糖发生酰胺化反应，在三乙胺碱性条件下脱除乙酸酯基，得到N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物；合成路线如下所示：
3.权利要求1所述的N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物在非诊断检测一氧化碳，或非诊断荧光光谱检测，或非诊断细胞、组织、活体成像中的应用。
4.根据权利要求3所述的应用，其特征在于，N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物作为探针在检测肝细胞或肝组织中的一氧化碳的应用。
5.一种肝靶向荧光探针，其特征在于，化学分子式为C22H28N4O12，化学结构式如式I所示：
式I。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010588544.XA CN111748003B (zh) | 2020-06-24 | 2020-06-24 | N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010588544.XA CN111748003B (zh) | 2020-06-24 | 2020-06-24 | N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111748003A CN111748003A (zh) | 2020-10-09 |
| CN111748003B true CN111748003B (zh) | 2021-10-15 |
Family
ID=72676975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010588544.XA Expired - Fee Related CN111748003B (zh) | 2020-06-24 | 2020-06-24 | N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111748003B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116496202B (zh) * | 2023-05-06 | 2024-03-01 | 安徽工业大学 | 一种用于氯磷酸二乙酯检测的荧光探针及其制备方法与应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622540A (zh) * | 2015-12-24 | 2016-06-01 | 华南理工大学 | 一种co探针及其制备方法和应用 |
| CN105623647A (zh) * | 2016-01-29 | 2016-06-01 | 山东师范大学 | 一种检测细胞内co的荧光探针及其制备方法和应用 |
| CN109574880A (zh) * | 2017-09-29 | 2019-04-05 | 华东理工大学 | 一种荧光探针及其制备方法和用途 |
| CN110343081A (zh) * | 2019-07-31 | 2019-10-18 | 湘潭大学 | 一种具有聚集诱导发光性质的荧光酸酐类化合物及其制备方法和应用 |
| CN110396121A (zh) * | 2016-12-16 | 2019-11-01 | 嘉应学院医学院 | 肝癌靶向糖配体分子及其制备方法和载药系统 |
-
2020
- 2020-06-24 CN CN202010588544.XA patent/CN111748003B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622540A (zh) * | 2015-12-24 | 2016-06-01 | 华南理工大学 | 一种co探针及其制备方法和应用 |
| CN105623647A (zh) * | 2016-01-29 | 2016-06-01 | 山东师范大学 | 一种检测细胞内co的荧光探针及其制备方法和应用 |
| CN110396121A (zh) * | 2016-12-16 | 2019-11-01 | 嘉应学院医学院 | 肝癌靶向糖配体分子及其制备方法和载药系统 |
| CN109574880A (zh) * | 2017-09-29 | 2019-04-05 | 华东理工大学 | 一种荧光探针及其制备方法和用途 |
| CN110343081A (zh) * | 2019-07-31 | 2019-10-18 | 湘潭大学 | 一种具有聚集诱导发光性质的荧光酸酐类化合物及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| A Fluorescent ESIPT Probe for Imaging CO-Releasing Molecule-3 in Living Systems;Weiyong Feng et al.;《Anal. Chem.》;20190610;第91卷;第8602-8606页 * |
| 检测一氧化碳分子荧光探针的研究进展;魏超 等;《有机化学》;20191231;第39卷;第3375-3383页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111748003A (zh) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Sensitive and selective off–on rhodamine hydrazide fluorescent chemosensor for hypochlorous acid detection and bioimaging | |
| Peng et al. | A novel fluorescent probe for selective detection of hydrogen sulfide in living cells | |
| CN110437199B (zh) | 一种硒半胱氨酸近红外荧光探针及其制备方法和应用 | |
| Zhu et al. | A novel highly sensitive fluorescent probe for bioimaging biothiols and its applications in distinguishing cancer cells from normal cells | |
| CN113121520B (zh) | 一种具有aie+esipt+ict机制的荧光染料和荧光探针及其制备方法与应用 | |
| CN111748005B (zh) | GalNAc修饰的美兰衍生物、制备方法与应用及肝靶向荧光探针、HClO检测方法 | |
| CN111748003B (zh) | N-乙酰胺基半乳糖修饰的3-硝基邻苯二甲酰亚胺衍生物、制备方法与应用及肝靶向探针 | |
| CN110092773A (zh) | 一种氧杂蒽类衍生物及其制备方法和应用 | |
| CN114181204A (zh) | 一种检测粘度的近红外荧光探针及其制备和应用 | |
| Wu et al. | A near-infrared fluorescent probe of dicyanoisophorone derivatives for selective detection and fluorescence cellular imaging of Palladium | |
| CN111778014A (zh) | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 | |
| CN112694471B (zh) | 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 | |
| CN110655510B (zh) | 一种靶向脂滴的亚硫酸盐比率荧光探针及其应用 | |
| CN111393401A (zh) | 一种基于罗丹明衍生物检测心肌黄酶的荧光探针分子及制备方法和用途 | |
| CN108373464B (zh) | 一类基于甲醛诱导催化琥珀酰亚胺水解的甲醛荧光探针及其制备方法和应用 | |
| CN116375692A (zh) | 一种用于检测半胱氨酸的近红外荧光分子探针及其制备方法和试剂盒 | |
| CN112457360B (zh) | 一种肝靶向的过氧亚硝酸根荧光探针及制备方法和应用 | |
| CN109400616B (zh) | 一种二氧化硫衍生物荧光探针及其制备方法和应用 | |
| CN110041314B (zh) | 一种用于检测水合肼的水溶性比率型荧光探针 | |
| CN113788821A (zh) | 近红外联氨化合物、制备方法以及甲醛检测试剂盒和应用 | |
| CN113582950A (zh) | 一种比率型多硫化氢荧光探针及其制备方法和应用 | |
| CN114507204B (zh) | 一种高尔基体靶向超氧阴离子荧光探针及其制备方法和应用 | |
| CN116284024B (zh) | 能分别和同时检测一氧化氮和二氧化硫的单分子荧光探针 | |
| CN115073434B (zh) | 一种检测肼的近红外荧光探针及其制备方法和应用 | |
| CN114380862B (zh) | 一种比率型光学/光声双模式荧光探针dop-hno及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230613 Address after: No.18-C1745, Jianshe Road, Kaixuan Avenue, Liangxiang, Fangshan District, Beijing 102488 Patentee after: Beijing Yigao Technology Co.,Ltd. Address before: 071002 No. 54 East 180 Road, Hebei, Baoding Patentee before: HEBEI University |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211015 |